Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03973047 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran
A Phase 1 study, sponsored by AMAG Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 228
- Enrollment target
NCT03973047 is a Phase 1 study that has completed, run by AMAG Pharmaceuticals. The registered enrollment target is 228 participants.
The verdict
NCT03973047, a Phase 1 study, has completed, sponsored by AMAG Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 228 participants
- Enrollment target
Study Summary
This is a Phase 1, randomized study to evaluate the rate of nausea in healthy premenopausal study participants following a single dose of BMT with or without a single 8 mg po dose of Zofran given 30 minutes before BMT dosing.
Interventions
- DRUG Placebo
- DRUG Bremelanotide
- DRUG Zofran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 228 participants |
| Start Date | 2019-06-17 |
| Est. Completion | 2019-07-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03973047
The ClinicalTrials.gov registry entry for NCT03973047 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 228 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AMAG Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03973047 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03973047 about?
NCT03973047 is a clinical study titled "Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran". This is a Phase 1, randomized study to evaluate the rate of nausea in healthy premenopausal study participants following a single dose of BMT with or without a single 8 mg po dose of Zofran given 30 minutes before BMT dosing.
What is the current status of trial NCT03973047?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 228 participants. The study started on 2019-06-17. Estimated completion is 2019-07-20.
What interventions are being tested in trial NCT03973047?
The interventions under investigation include: Placebo (DRUG), Bremelanotide (DRUG), Zofran (DRUG).
Who is sponsoring clinical trial NCT03973047?
This trial is sponsored by AMAG Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.